NAD+ Precursor Chews vs. Fish Oil for Senior Dog Vitality: What the Evidence Actually Supports

By Koranda Walsh, VMD, DACVIM (SAIM), DACVP (CP)

✓ Medically reviewed by Koranda Walsh, VMD, DACVIM (SAIM), DACVP (CP) — August 11, 2026 For general education — not a substitute for veterinary care.

Comparisons · August 16, 2026 · 7 min read

Fish oil has decades of dosed evidence behind it; NAD+ chews have one small trial and a marketing head start.

My call up front: if you’re choosing one supplement for an aging dog, fish oil is the one with the evidence to justify the spend. NAD+ precursor chews aren’t a scam, but they’re a newer, thinner-evidenced category riding on a genuinely interesting human-longevity story that hasn’t yet been replicated at scale in dogs.

Before you buy either one, check:

• Does the fish oil product state actual EPA/DHA milligrams per chew or capsule, not just “fish oil” on the front label?
• Is the NAD+ chew’s active ingredient named and dosed (nicotinamide riboside, NR, or a nicotinamide mononucleotide) rather than hidden behind a proprietary blend?
• Has your dog had recent bloodwork — specifically triglycerides and a lipid panel — that would change how much fish oil is safe to add?
• Is there a NASC seal or third-party Certificate of Analysis you can actually find, not just a claim of one?
• Are you trying to address a named problem (stiffness, dull coat, slowing gait) or a vague “vitality” goal? The answer changes which ingredient earns priority.
• Does the product make a lifespan claim (“adds years”) anywhere on the label or site? That’s a red flag regardless of which category it’s in.

I read labels the way I read a chemistry panel: for what’s actually there, not what the packaging implies. Below is the scoring behind that checklist.

The myth: “vitality” supplements are interchangeable

Both categories get marketed under the same word — vitality — and that’s the problem. Fish oil and NAD+ precursors don’t do the same job in a senior dog’s body, and treating them as competing options for the same shelf slot is where owners get steered wrong. Fish oil supplies long-chain omega-3 fatty acids (EPA and DHA) that get incorporated into cell membranes and modulate inflammatory signaling. NAD+ precursors supply a substrate for cellular energy metabolism and DNA repair pathways that naturally decline with age. They’re not rivals. They’re not substitutes. And the evidence base behind each is not remotely the same size.

In my practice, the dogs who get “vitality chews” added to their routine are almost never the dogs with a diagnosed problem — they’re the dogs whose owners noticed something soft and hard to name. I saw a 10-year-old spayed female Labrador, about 68 pounds, brought in because she’d stopped jumping into the back of the SUV that spring, something she’d done without hesitation for eight years. Her owner had already started her on an NAD+ chew two months earlier, based on a podcast recommendation, with no change in the jumping. Her bloodwork showed a mildly elevated ALT and a triglyceride level that was fine but worth tracking given her breed. We started omega-3s at a joint-support dose, rechecked her lipid panel at eight weeks to make sure the added fat load wasn’t pushing triglycerides up, and by the twelve-week recheck her owner reported she was back to jumping in “most days.” That’s one dog, not a trial — but it’s the pattern I see most often: an ingredient chosen for its story, not for what the dog’s actual presentation calls for.

What the NAD+ precursor trial actually showed — and didn’t

The strongest data point for canine NAD+ supplementation is a randomized, placebo-controlled trial of a combined senolytic and NAD+ precursor (LY-D6/2), published in Scientific Reports. Seventy dogs with mild to moderate cognitive impairment were split into placebo, low-dose, and full-dose groups. Outcomes were owner-reported scores on the Canine Cognitive Dysfunction Rating (CCDR) scale plus objective physical-activity monitoring. Fifty-nine dogs completed the three-month primary endpoint and 51 reached the six-month secondary endpoint; the full-dose group showed improved owner-assessed cognitive scores relative to placebo.

That’s a real, well-designed study — and it’s also one trial, in dogs already showing cognitive impairment, using a specific combination product rather than an NAD+ precursor alone. It tells you something about a senolytic-plus-precursor combination in cognitively impaired dogs. It does not tell you that an NAD+ chew will improve “vitality” in a healthy senior dog with no cognitive symptoms, and no product on the market has replicated this exact result with NAD+ precursor alone. Separately, a safety review of nicotinamide riboside chloride — the precursor form most common in these chews — found that repeated 90-day dosing in dogs produced no significant adverse effects, per an PMC: EFSA-referenced safety assessment. Safe is a lower bar than effective, and both matter separately.

Where fish oil’s evidence is deeper

Omega-3 fatty acids have a longer, broader research base in dogs, covering joint comfort, skin and coat, and — closer to the “vitality” framing — cognition. A study on dietary supplementation with a nutrient blend containing arginine, antioxidants, B vitamins, and fish oil found PubMed: cognitive enhancement in old dogs, though it’s worth noting fish oil was one component of a multi-ingredient blend, not tested alone. The American Kennel Club summarizes the broader literature on EPA/DHA supporting joint comfort and coat quality in aging dogs, which lines up with what most senior-dog exam rooms see reflected in owner reports.

The tradeoff with fish oil isn’t efficacy, it’s dosing and format. Too much, too fast, in a dog with borderline lipid values can push triglycerides higher, which is why I check a lipid panel before recommending a real dose rather than the label’s blanket suggestion. If your dog already has a diagnosed inflammatory joint condition, the distinction between ordinary aging stiffness and arthritis matters for how much omega-3 dosing actually helps versus how much it should be paired with other management — a distinction I cover in more depth in Arthritis vs. Normal Aging Stiffness in Dogs.

Reading the label the way you’d read a chemistry panel

An analyte on a lab report only means something in the context of a reference interval — a triglyceride value of 200 mg/dL reads differently in a Miniature Schnauzer than in a Greyhound. Supplement labels deserve the same scrutiny. “NAD+ precursor” without a stated milligram dose of nicotinamide riboside or nicotinamide mononucleotide is a marketing phrase, not a spec. “Fish oil” without an EPA/DHA milligram count per chew tells you almost nothing about diagnostic-grade omega-3 dosing. I want the analyte named and the amount quantified before I’ll credit a claim, and I’d extend that same standard to any product regardless of category or price point.

Format matters here too, and not in the way marketing usually frames it. A precursor delivered in a chew still has to survive first-pass metabolism the same way it would in a capsule; the chew format is a palatability and compliance choice more than a bioavailability one. If you’re managing a household with more than one supplement and more than one dog size, the practical mechanics of dosing chews accurately are worth its own read — see Chew vs Powder vs Liquid Supplements for Dogs for how format actually changes diagnostic yield in practice.

Fish oil isn’t the only anti-inflammatory ingredient owners ask me to compare against something newer, either. The same evidence-first scoring applies when owners bring me a postbiotic product and ask whether it beats omega-3s for a dog with intermittent GI or skin inflammation — a comparison I walk through in Postbiotics vs. Fish Oil for Dog Inflammation.

The owners I see most often aren’t choosing between NAD+ chews and fish oil in the abstract — they’re standing in an aisle or scrolling a product page with a specific dog in mind, usually one who’s slowed down in some way they can point to. A few months back I worked with a 12-year-old neutered male Cavalier, mildly overweight at 19 pounds, whose owner described him sleeping through most of the afternoon and needing help onto the couch, a change she’d noticed over about six weeks. She was weighing a $65 NAD+ chew subscription against a $30 fish oil that needed refrigeration and a syringe for dosing — a real tradeoff between convenience and a slightly less pleasant routine. We ran bloodwork first. His cognitive screening didn’t flag dysfunction, but his gait and mild weight gain pointed toward joint discomfort as the more likely driver of the couch-jumping change. We started with dosed fish oil and a weight-management conversation rather than the NAD+ chew, because the evidence for his actual presentation pointed there first.

A practical sequence for senior-dog owners

1. Get current bloodwork, including a lipid panel, before adding either supplement — this determines your fish oil dosing ceiling and rules out other causes of the “vitality” complaint.
2. Name the specific change you’re seeing (gait, sleep, coat, cognition) rather than shopping for a generic “vitality” fix.
3. If the concern is joints, skin, coat, or general inflammation, start with a dosed fish oil product that states EPA/DHA milligrams per serving.
4. If the concern is specifically cognitive — disorientation, altered sleep-wake cycles, house-training lapses in a previously reliable dog — an NAD+ precursor is a reasonable add-on to discuss with your vet, with expectations set by the single trial behind it, not the marketing copy.
5. Recheck bloodwork at 8–12 weeks if you’ve started fish oil at a therapeutic dose, and track the specific symptom you named in step 2, not a vague sense of “doing better.”

Where this leaves the verdict

Fish oil is the better-supported default for most senior dogs because the evidence spans joints, coat, and some cognitive outcomes, and dosing is well characterized enough to titrate against real bloodwork. NAD+ precursor chews aren’t disqualified — the Scientific Reports trial is a legitimate, well-designed data point — but it’s one combination product, in cognitively impaired dogs, not a blanket “vitality” claim for every aging dog. Read the label and the bloodwork before you read the claim on the front of either box.